Newsroom | Medtronic | 2019 Press Releases

2019 Press Releases


201920182017201620152014
Search News Releases
 
DateTitle  
04/17/19Medtronic Data Expands on Key Aortic Solutions for Challenging Anatomies
(GLOBE NEWSWIRE via COMTEX) --New EndoSuture Aneurysm Repair (ESAR) and Valiant Navion(TM) Data Presented at Charing Cross Demonstrate Safety and Efficacy in Patients with Complex Anatomies DUBLIN and LONDON - April 17, 2019 - Medtronic plc (NYSE:MDT) today released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant(TM) II/IIs stent graft system in combination with Heli-FX(TM) EndoAnchor(TM) implants and for the Valiant Navion(TM) thoracic stent graf... 
 Printer Friendly Version
04/17/19Medtronic VenaSeal(TM) Closure System Demonstrates Durable and Consistent Outcomes at Five Years in Patients with Chronic Venous Disease
(GLOBE NEWSWIRE via COMTEX) --DUBLIN and LONDON - April 17, 2019 - Medtronic plc (NYSE:MDT) today announced five-year outcomes from the VeClose Extension Study. Nick Morrison, M.D., Center for Vein Restoration, Mesa, Ariz., presented at the 2019 Charing Cross Symposium in London. The new data demonstrate durable and consistent long-term outcomes of the Medtronic VenaSeal(TM) Closure System in treating patients with chronic venous disease. The VeClose Extension Study is a follow-on study with ... 
 Printer Friendly Version
04/08/19New Data Show Encouraging Economic Outcomes for Medtronic HeartWare(TM) HVAD(TM) System
Positive HVAD LATERALTM Study Results Also Now Published in   The Journal of Heart and Lung TransplantationDUBLIN and ORLANDO, Fla. - April 8, 2019 - Medtronic plc (NYSE:MDT) today announced data showing promising economic outcomes for the Medtronic HeartWare(TM) HVAD(TM) System after analyzing multiple clinical studies. The economic analyses of the HVAD System - a left ventricular assist device (LVAD) that helps a failing heart pump and increases the amount of blood that circulates throu... 
Download PDFPrinter Friendly Version
04/08/19New Value-Based Agreement Between Blue Cross and Blue Shield of Minnesota and Medtronic Leverages Diabetes Technology to Drive Positive Outcomes
  Agreement Focuses on the Guardian Connect Smart CGM System, Improved Member Engagement and Measuring Time in RangeMINNEAPOLIS and DUBLIN - April 8, 2019 - Blue Cross and Blue Shield of Minnesota and Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, announce a new outcomes-based agreement that provides members of the Blue Cross and Blue Shield of Minnesota plan who live with diabetes improved access to the Guardian(TM) Connect smart Continuous ... 
Download PDFPrinter Friendly Version
04/08/19New Study Finds Targeted Drug Delivery (TDD) is Associated with a Reduction in Health Care Utilization and Cost for Cancer Pain Patients
Savings Are Driven by Fewer Inpatient Visits, Shorter Inpatient Length of Stay, and Fewer Emergency Department VisitsDUBLIN - April 8, 2019 - Medtronic plc (NYSE:MDT) today announced results of a study published in JAMA Network Open that demonstrates a reduction in health care utilization and cost for cancer pain patients using targeted drug delivery (TDD) and conventional medical management (CMM) vs. CMM alone. The study found significant cost savings to payors, with fewer inpatient visits, sho... 
Download PDFPrinter Friendly Version
04/05/19Medtronic HeartWare(TM) HVAD(TM) System Demonstrates Reduction in Total Strokes, Disabling Strokes and Stroke-Related Mortality with Blood Pressure Management
Company Has Initiated a Post-Approval Study of Heart Failure Management Best Practices to Further Demonstrate Improved Patient OutcomesDUBLIN and ORLANDO, Fla. - April 5, 2019 - Medtronic plc (NYSE:MDT) today announced the results of an analysis on the impact of stroke severity in patients receiving its HeartWare(TM) HVAD(TM) System as destination therapy, showing that targeted blood pressure management helped reduce serious strokes. The HVAD System is a left ventricular assist device (LVAD) tha... 
Download PDFPrinter Friendly Version
03/25/19Medtronic Launches MedTech Innovation Accelerator in Shanghai
(GLOBE NEWSWIRE via COMTEX) --Early-Stage Business Accelerator to Empower Local MedTech Innovation and Enhance Medtronic China's Industry Leadership DUBLIN and SHANGHAI - March 25, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the launch of the Medtronic MedTech Innovation Accelerator in Pujiang International Science and Technology City at Minhang District, Shanghai. The new collaborative innovation platform will provide services for MedTech start-u... 
 Printer Friendly Version
03/17/19New Clinical Trial Shows Medtronic TYRX(TM) Envelope Significantly Reduces Major Infections in Cardiac Implantable Device Patients
Late-Breaking Trial Results Presented at ACC Scientific Sessions and   Published in The New England Journal of MedicineWRAP-IT is the Largest Randomized Global Trial Ever Conducted with Cardiac Implanted Electronic DevicesDUBLIN and NEW ORLEANS - March 17, 2019 - Medtronic plc (NYSE:MDT) today announced results from the landmark Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT), which demonstrated the TYRX(TM) Absorbable Antibacterial Envelope (TYRX envelope) reduce... 
Download PDFPrinter Friendly Version
03/16/19Medtronic Evolut Low Risk Trial Meets Primary Endpoint
Less Invasive Evolut™ Transcatheter Aortic Valve Replacement (TAVR) System Successful in Clinical Trial When Compared to Open Heart Surgery in Healthier Aortic Stenosis PatientsDUBLIN and NEW ORLEANS – March 16, 2019 – Medtronic plc (NYSE:MDT) today announced first-ever clinical data from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™ transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthi... 
Download PDFPrinter Friendly Version
03/14/19Medtronic Board Appoints Andrea J. Goldsmith, Ph.D. as a New Director
DUBLIN - March 14, 2019 - Medtronic plc (NYSE:MDT) today announced that its Board of Directors has appointed Andrea J. Goldsmith, Ph.D. to the Board as an independent director, effective March 11, 2019.Dr. Goldsmith is the Stephen Harris professor in the School of Engineering at Stanford University and director of Stanford's Wireless Systems Laboratory. Her research focuses on state-of-the-art wireless system design and the application of information theory and signal processing to neuroscience.... 
Download PDFPrinter Friendly Version
03/08/19Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2019
Board Authorizes $6 Billion for Share RepurchasesDUBLIN - March 8, 2018 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2019 fourth quarter cash dividend of $0.50 per ordinary share, representing a 9 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2018.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for ... 
Download PDFPrinter Friendly Version
03/07/19Medtronic Announces Closing of Public Offering of Senior Notes; Acceptance of Tendered Notes; and Redemption of Certain Senior Notes
DUBLIN - March 7, 2019 - Medtronic plc (the "Company") (NYSE:MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco") has closed a registered public offering (the "Offering") of €500,000,000 principal amount of Floating Rate Senior Notes due 2021, €1,500,000,000 principal amount of 0.000% Senior Notes due 2021, €1,500,000,000 principal amount of 0.375% Senior Notes due 2023, €1,500,000,000 principal amount of 1.125% Senior Notes due 2027, €1,000,... 
Download PDFPrinter Friendly Version
03/06/19Medtronic Announces the Pricing Terms of Its Cash Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
 DUBLIN - March 6, 2019 - Medtronic plc (the "Company") (NYSE:MDT) today announced the pricing terms of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc. and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors"), for any and all (the "Any and All Tender Offers") of the $3.1 billion in aggregate principal amount of the outstanding Notes listed in Table 1 below (the "Any and All Notes") and up to $3.7 billi... 
Download PDFPrinter Friendly Version
03/06/19Medtronic Announces the Early Results of its Cash Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - March 6, 2019 - Medtronic plc (the "Company") (NYSE:MDT) today announced that, pursuant to the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc. and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors") for any and all (the "Any and All Tender Offers") of the $3.1 billion in aggregate principal amount of the outstanding Notes listed in Table 1 below (the "Any and All Notes") and up to $3.7 billion (the "A... 
Download PDFPrinter Friendly Version
03/04/19Medtronic Announces Pricing of €7.0 Billion of Senior Notes
DUBLIN - March 4, 2019 - Medtronic plc (NYSE:MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering of €500,000,000 principal amount of floating rate senior notes due 2021, €1,500,000,000 principal amount of 0% senior notes due 2021, €1,500,000,000 principal amount of 0.375% senior notes due 2023, €1,500,000,000 principal amount of 1.125% senior notes due 2027, €1,000,000,000 principal amount of 1.625% senior notes due ... 
Download PDFPrinter Friendly Version
03/04/19Medtronic Announces the Upsizing of its Maximum Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - March 4, 2019 - Medtronic plc (the "Company") (NYSE:MDT) today announced the upsizing of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc. and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors") for up to $1.9 billion combined aggregate purchase price (excluding accrued and unpaid interest to, but not including, the applicable settlement date and excluding fees and expenses related to the tender off... 
Download PDFPrinter Friendly Version
03/01/19Medtronic Statement Regarding IN.PACT Paclitaxel Safety Analysis Correction Letter in The Journal of the American College of Cardiology
DUBLIN - March 1, 2019 - On February 15, 2019, Medtronic issued a statement regarding a programming error in the clinical data reporting isolated to the two and three year follow-up periods in our IN.PACT Global post-market study, part of the IN.PACT Admiral clinical program for the treatment of femoropopliteal artery disease. As we noted in our previous statement, this programming error impacted the IN.PACT Paclitaxel Safety analysis, which recently presented at th... 
Download PDFPrinter Friendly Version
03/01/19Medtronic EVP & CFO Karen L. Parkhill to Speak at Barclays Global Healthcare Conference
DUBLIN - March 1, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Barclays Global Healthcare Conference 2019 on Tuesday, March 12, 2019, in Miami, Florida.Karen Parkhill, executive vice president and chief financial officer of Medtronic, will answer questions about the company beginning at 9:00 a.m. EDT (8:00 a.m. CDT).A live audio webcast of the presentation will be available on March 12, 2019, by clicking on the Investors Eve... 
Download PDFPrinter Friendly Version
03/01/19Medtronic EVP & MITG President Bob White to Speak at Cowen Healthcare Conference
DUBLIN - March 1, 2019 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019, in Boston, Massachusetts.Bob White, executive vice president and president of Medtronic's Minimally Invasive Therapies Group (MITG), will answer questions about the company beginning at 11:20 a.m. EDT (10:20 a.m. CDT).A live audio webcast of the presentation will be available on March... 
Download PDFPrinter Friendly Version
02/28/19Medtronic Announces Approval and Launch of Japan's First DBM Bone Grafting Product for Spine and Orthopedic Procedures
Grafton(TM) DBM Product Will Provide More Options for Spine and Orthopedic Surgeons in JapanDUBLIN and TOKYO - February 28, 2019 - Medtronic plc (NYSE:MDT) announced today the Japanese launch of the Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine and orthopedic procedures. Grafton DBM is the first and only demineralized bone matrix product available in Japan, the world's second largest market for spinal medical devices. Due to its long clinical history, proven perform... 
Download PDFPrinter Friendly Version
02/27/19Medtronic Announces FDA Clearance and U.S. Launch of the Accurian Radio Frequency System for Nerve Tissue Ablation
Medtronic Expands Pain Portfolio with Minimally Invasive Therapy to Support Patients Throughout the Care ContinuumDUBLIN - February 27, 2019 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Accurian(TM) RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues. RF ablation is a minimally invasive procedure in which current produced by radio waves heats up a small area of nerve tissue to stop it from sending pain ... 
Download PDFPrinter Friendly Version
02/26/19Medtronic Resolute(TM) Drug-Eluting Stent (DES) Platform Receives Expanded Indication for Treatment of Chronic Total Occlusion (CTO)
FDA Approval Allows Interventional Cardiologists Access to Resolute DES Technology to Treat De Novo CTODUBLIN - February 26, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute Onyx(TM) and Resolute Integrity(TM) DES) for the treatment of patients with coronary artery disease who have de novo chronic total occlusion (CTO), a complex vessel condition involving complete blocka... 
Download PDFPrinter Friendly Version
02/25/19Medtronic Wraps Up Scientific Data Presentations at the Advanced Technologies and Treatments for Diabetes International Conference
DUBLIN - February 25, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a successful conclusion to the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), which took place in Berlin from February 20 - 23, 2019.At this year's conference, the Diabetes Group at Medtronic presented a range of scientific data focusing on the company's latest MiniMed(TM) 670G system and its exclusive SmartGuard(TM) technology, includ... 
 Printer Friendly Version
02/20/19Medtronic EVP & RTG President Geoff Martha to Speak at Leerink Partners Global Healthcare Conference
DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 8th Annual Leerink Partners Global Healthcare Conference in New York.    Geoff Martha, executive vice president and president of the Restorative Therapies Group (RTG) of Medtronic, will make a brief presentation and answer questions on the company, beginning at 9:00 a.m. EST (8:00 a.m. CST) on Wednesday, February 27, 2019.    A live audio webcast of the prese... 
Download PDFPrinter Friendly Version
02/20/19Medtronic Announces U.S. Commercial Launch of Deep Brain Stimulation for Medically-Refractory Epilepsy
With Official Launch and First Implant, Several Health Insurers Now Consider     DBS Therapy for Epilepsy a Covered IndicationDUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT) today announced both the U.S. launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy and the first commercially implanted patient at Emory University in Atlanta, Ga. According to the Epilepsy Foundation, as many as 3.4 million Americans have epilepsy1, with one-third estimated to be drug resist... 
Download PDFPrinter Friendly Version
02/20/19Medtronic Announces Cash Tender Offer for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - February 20, 2019 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of a cash tender offer by its indirectly wholly owned subsidiaries, Medtronic, Inc. ("Medtronic, Inc.") and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors"), for any and all (the "Any and All Tender Offers") of the outstanding Securities listed in Table 1 below and up to $1.9 billion (the "Aggregate Maximum Purchase Price") combined aggregate pur... 
Download PDFPrinter Friendly Version
02/19/19Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management
(GLOBE NEWSWIRE via COMTEX) --DUBLIN - February 19, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL technology is designed to automate insulin delivery in a way that is real-time, personalized and adapts to the user. The system will also provide insights and predicti... 
 Printer Friendly Version
02/19/19Medtronic Reports Third Quarter Financial Results
  Revenue of $7.5 Billion Increased 2.4% Reported; Increased 4.4% Organic   GAAP Diluted EPS of $0.94; Non-GAAP Diluted EPS of $1.29 Operating Margin of 20.4% Increased 90 bps; Non-GAAP Operating Margin of 29.2% Increased 140 bps  Cash Flow from Operations of $4.9 Billion in First Nine Months vs. $3.6 Billion in Prior Year; Free Cash Flow of $4.1 Billion in First Nine Months vs. $2.9 Billion in Prior Yea   Company Raises FY19 EPS and Free Cash Flow Guidance  ... 
Download PDFPrinter Friendly Version
02/17/19Medtronic Announces Preliminary PRODIGY Results: a Global Study to Identify Patients at High Risk for Opioid-Induced Respiratory Compromise
Groundbreaking Microstream(TM) Capnography Study Provides Easy-to-Use Risk Prediction ToolStudy Found Greater Than 40 Percent of Patients on Hospital General Care Floor Experience Opiod-Induces Respiratory DepressionDUBLIN and SAN DIEGO - February 17, 2019 - Medtronic plc (NYSE:MDT) today announced preliminary results from PRODIGY, a Medtronic-sponsored, prospective, multi-center study to identify people at high risk for opioid-induced respiratory depression (OIRD), a form of respiratory co... 
Download PDFPrinter Friendly Version
02/15/19Medtronic Statement Regarding Revised IN.PACT Post Market Study Data
Medtronic Statement Regarding Revised IN.PACT Post Market Study Data DUBLIN - February 15, 2019 - Medtronic plc (NYSE:MDT) today issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the clinical data reporting isolated to the two- and three-year follow-up periods in our IN.PACT Global post-market study, part of the IN.PACT Admiral clinical program for the treatment of femoropopliteal artery disease. Preliminary results ... 
 Printer Friendly Version
02/14/19Medtronic and Medical University of South Carolina Partner to Improve Patient Outcomes
   Value-Based Health Care Partnership Will Target   Acute Conditions and Chronic Diseases in South CarolinaDUBLIN and CHARLESTON, S.C. - February 14, 2019 - Medtronic plc (NYSE:MDT) and the Medical University of South Carolina (MUSC) today announced a five-year value-based health care partnership intended to transform and improve care for patients in South Carolina. The collaboration will focus on developing solutions that improve the health outcomes and care experiences for pa... 
Download PDFPrinter Friendly Version
02/08/19Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2019
DUBLIN - February 8, 2019 - Medtronic plc (NYSE:MDT) announced today that it will report financial results for the third quarter of fiscal year 2019 on Tuesday, February 19 , 2019. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2019, which ended on Friday, January 25, 2019.Medtronic will host a web... 
Download PDFPrinter Friendly Version
02/07/19Medtronic Receives FDA Approval on Expanded Indication for Pipeline Flex Embolization Device
Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain AneurysmsDUBLIN - February 7, 2019 - Medtronic plc (NYSE:MDT) announced today that it has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex embolization device.1Previously indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms (IAs) in the interna... 
Download PDFPrinter Friendly Version
01/30/19Medtronic Valiant(TM) Captivia(TM) Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients
New RESCUE Trial Data Presented in Blunt Thoracic Aortic InjuryDUBLIN and SAN DIEGO - January 30, 2019 - Medtronic plc (NYSE:MDT) today announced new data supporting the long-term durability, safety, and efficacy of the Valiant(TM) Captivia(TM) thoracic stent graft system for the treatment of blunt thoracic aortic injury (BTAI). The presentation by Himanshu J. Patel, M.D., University of Michigan Department of Cardiac Surgery at The Society of Thoracic Surgeons Annual Meeting, was the first and o... 
Download PDFPrinter Friendly Version
01/30/19Medtronic Announces Positive Results from the Largest ENB Study to Aid in Lung Cancer Diagnosis, Staging, and Treatment Preparation in a Single Minimally Invasive Procedure
Company Is Committed to Leading Evidence Generation Across the Lung Cancer Care ContinuumMedtronic Initiates Separate Study to Evaluate the Safety and Performance of the Emprint(TM) Ablation Catheter with the superDimension(TM) Navigation System for Lung Ablation ProceduresDUBLIN - January 30, 2019 - Medtronic plc (NYSE:MDT) today announced that the Journal of Thoracic Oncology has published 12-month results of the NAVIGATE study, the largest, prospective, multicenter trial evaluating electromag... 
Download PDFPrinter Friendly Version
01/28/19Medtronic Announces U.S. Commercial Launch of Mazor X Stealth(TM) Edition for Robotic-Assisted Spine Surgery
First U.S. Patients Treated Using Mazor X Stealth(TM) Edition at Norton Healthcare and Reston Hospital CenterDUBLIN - January 28, 2019 - Medtronic plc (NYSE:MDT) today announced the first U.S. patients treated with the Mazor X Stealth(TM) Edition for spine surgery following its recent commercial launch. The Mazor X Stealth Edition offers a fully-integrated procedural solution for surgical planning, workflow, execution and confirmation. The system was first used at Norton Healthcare in Louisville... 
Download PDFPrinter Friendly Version
01/24/19Medtronic to Acquire EPIX Therapeutics, Expanding Its Cardiac Ablation Portfolio
(GLOBE NEWSWIRE via COMTEX) --DiamondTemp Ablation System Represents Disruptive RF Innovation DUBLIN - January 24, 2019 - Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of patients with cardiac arrhythmias (irregular heartbeats), including atrial fibr... 
Download PDFPrinter Friendly Version
01/22/19Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB
Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data TransparencyDUBLIN and LEIPZIG, Germany - January 22, 2019 - Medtronic plc (NYSE:MDT) today announced new data shared on the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Outcomes from the IN.PACT DCB Paclitaxel Safety Analysis, an independent, patient-level survival analysis inclusive of all IN.PACT DCB clinica... 
Download PDFPrinter Friendly Version
01/17/19Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery
Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral OpioidsDUBLIN - January 17, 2019 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Embrace TDD (targeted drug delivery) clinical study that will evaluate the use of the SynchroMed(TM) II intrathecal drug delivery system ("Medtronic pain pump") as an alternative to oral opioids for patients with chronic... 
Download PDFPrinter Friendly Version
01/15/19Medtronic Launches Mobile App That Communicates Directly with World's First Smartphone-Connected Pacemakers
MyCareLink Heart(TM) Mobile App Allows Pacemaker Patients to Easily Stay Connected with Their ClinicsDUBLIN - January 15, 2019 - Medtronic plc (NYSE:MDT) today announced the launch of its MyCareLink Heart(TM) mobile app to support the world's first and only portfolio of pacemakers that can communicate directly with patients' smartphones and tablets.Compatible with Medtronic BlueSync(TM) technology-enabled pacemakers, the MyCareLink Heart mobile app is designed to securely and wirelessly send dev... 
Download PDFPrinter Friendly Version
01/09/19Medtronic Foundation Recognizes 12 Bakken Invitation Honorees For Driving Positive Change In Healthcare
Program Celebrates the Legacy of Medtronic Co-Founder Earl Bakken and Other Outstanding Patient Advocates Around the WorldMINNEAPOLIS and Kona, Hawaii - January 9, 2019 - The Medtronic Foundation today announced 12 individuals from around the world as recipients of the 2018 Bakken Invitation. This Medtronic Foundation program recognizes and connects people who "live on, give on and dream on" through their advocacy, contributions to innovation and volunteerism after overcoming health challenges w... 
Download PDFPrinter Friendly Version
01/03/19New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health
Untitled Document IQcast Feature Aims to Predict the Likelihood of a Low Glucose Event Up to Four Hours in AdvanceDUBLIN and CAMBRIDGE, Mass. - January 3, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced a new feature for the Sugar.IQ(TM) personal diabetes assistant app called IQcast(TM). Using artificial intelligence (AI) technology from IBM Wat... 
Download PDFPrinter Friendly Version
X